Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 135 entries
Sorted by: Best Match Show Resources per page
Substrate Specificity of the .

Frontiers in microbiology

Derouiche A, Shi L, Kalantari A, Mijakovic I.
PMID: 27725816
Front Microbiol. 2016 Sep 26;7:1525. doi: 10.3389/fmicb.2016.01525. eCollection 2016.

Bacterial protein-tyrosine kinases (BY-kinases) are known to regulate different aspects of bacterial physiology, by phosphorylating cellular protein substrates. Physiological cues that trigger BY-kinases activity are largely unexplored. In

Cite
Derouiche A, Shi L, Kalantari A, et al. Substrate Specificity of the . Front Microbiol. 2016;7:1525doi: 10.3389/fmicb.2016.01525.
Derouiche, A., Shi, L., Kalantari, A., & Mijakovic, I. (2016). Substrate Specificity of the . Frontiers in microbiology, 71525. https://doi.org/10.3389/fmicb.2016.01525
Derouiche, Abderahmane, et al. "Substrate Specificity of the ." Frontiers in microbiology vol. 7 (2016): 1525. doi: https://doi.org/10.3389/fmicb.2016.01525
Derouiche A, Shi L, Kalantari A, Mijakovic I. Substrate Specificity of the . Front Microbiol. 2016 Sep 26;7:1525. doi: 10.3389/fmicb.2016.01525. eCollection 2016. PMID: 27725816; PMCID: PMC5035731.
Copy Download .nbib Format: NLM
Oncogenes, Protein Tyrosine Kinases, and Signal Transduction.

Journal of biomedical science

Liu D, Wang LH.
PMID: 11725009
J Biomed Sci. 1994 Mar;1(2):65-82. doi: 10.1007/BF02257980.

Many oncogenes encode protein tyrosine kinases (PTKs). Oncogenic mutations of these genes invariably result in constitutive activation of these PTKs. Autophosphorylation of the PTKs and tyrosine phosphorylation of their cellular substrates are essential events for transmission of the mitogenic...

Cite
Liu D, Wang LH. Oncogenes, Protein Tyrosine Kinases, and Signal Transduction. J Biomed Sci. 1994;1(2):65-82doi: 10.1007/BF02257980.
Liu, D., & Wang, L. H. (1994). Oncogenes, Protein Tyrosine Kinases, and Signal Transduction. Journal of biomedical science, 1(2), 65-82. https://doi.org/10.1007/BF02257980
Liu, D., and Wang, L.-H.. "Oncogenes, Protein Tyrosine Kinases, and Signal Transduction." Journal of biomedical science vol. 1,2 (1994): 65-82. doi: https://doi.org/10.1007/BF02257980
Liu D, Wang LH. Oncogenes, Protein Tyrosine Kinases, and Signal Transduction. J Biomed Sci. 1994 Mar;1(2):65-82. doi: 10.1007/BF02257980. PMID: 11725009.
Copy Download .nbib Format: NLM
Signal transduction drug discovery: targets, mechanisms and structure-based design.

Current opinion in drug discovery & development

Dalgarno DC, Metcalf CA, Shakespeare WC, Sawyer TK.
PMID: 19649883
Curr Opin Drug Discov Devel. 2000 Sep;3(5):549-64.

Signal transduction targets include catalytic and/or non-catalytic domains, which are critical to various aspects of cell growth, differentiation, metabolism and function, mitogenesis, motility and gene transcription. Specific examples of molecular targets include the catalytic domains of protein tyrosine kinases...

Cite
Dalgarno DC, Metcalf CA, Shakespeare WC, et al. Signal transduction drug discovery: targets, mechanisms and structure-based design. Curr Opin Drug Discov Devel. 2000;3(5):549-64
Dalgarno, D. C., Metcalf, C. A., Shakespeare, W. C., & Sawyer, T. K. (2000). Signal transduction drug discovery: targets, mechanisms and structure-based design. Current opinion in drug discovery & development, 3(5), 549-64.
Dalgarno, D C, et al. "Signal transduction drug discovery: targets, mechanisms and structure-based design." Current opinion in drug discovery & development vol. 3,5 (2000): 549-64.
Dalgarno DC, Metcalf CA, Shakespeare WC, Sawyer TK. Signal transduction drug discovery: targets, mechanisms and structure-based design. Curr Opin Drug Discov Devel. 2000 Sep;3(5):549-64. PMID: 19649883.
Copy Download .nbib Format: NLM
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

American journal of translational research

Yin M, Guan X, Liao Z, Wei Q.
PMID: 19956424
Am J Transl Res. 2009 Jan 30;1(2):101-14.

Lung cancer leads all other cancers in both incidence and mortality. Recent advances in underlying molecular pathogenesis have validated a panel of protein tyrosine kinases as new targets in lung cancer treatment. Insulin-like growth factor-1 receptor (IGF-1R) is an...

Cite
Yin M, Guan X, Liao Z, et al. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res. 2009;1(2):101-14
Yin, M., Guan, X., Liao, Z., & Wei, Q. (2009). Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. American journal of translational research, 1(2), 101-14.
Yin, Ming, et al. "Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review." American journal of translational research vol. 1,2 (2009): 101-14.
Yin M, Guan X, Liao Z, Wei Q. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res. 2009 Jan 30;1(2):101-14. PMID: 19956424; PMCID: PMC2776317.
Copy Download .nbib Format: NLM
Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Journal of cell communication and signaling

Xu Y, Fisher GJ.
PMID: 22851429
J Cell Commun Signal. 2012 Aug;6(3):125-38. doi: 10.1007/s12079-012-0171-5. Epub 2012 Aug 01.

Protein tyrosine phosphorylation is a fundamental regulatory mechanism controlling cell proliferation, differentiation, communication, and adhesion. Disruption of this key regulatory mechanism contributes to a variety of human diseases including cancer, diabetes, and auto-immune diseases. Net protein tyrosine phosphorylation is...

Cite
Xu Y, Fisher GJ. Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease. J Cell Commun Signal. 2012;6(3):125-38doi: 10.1007/s12079-012-0171-5.
Xu, Y., & Fisher, G. J. (2012). Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease. Journal of cell communication and signaling, 6(3), 125-38. https://doi.org/10.1007/s12079-012-0171-5
Xu, Yiru, and Fisher, Gary J. "Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease." Journal of cell communication and signaling vol. 6,3 (2012): 125-38. doi: https://doi.org/10.1007/s12079-012-0171-5
Xu Y, Fisher GJ. Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease. J Cell Commun Signal. 2012 Aug;6(3):125-38. doi: 10.1007/s12079-012-0171-5. Epub 2012 Aug 01. PMID: 22851429; PMCID: PMC3421019.
Copy Download .nbib Format: NLM
Protein tyrosine kinase panel as a tool for anticancer drug design.

Acta naturae

Rakitina TV, Yudkina OV, Smirnova EV, Lipkin AV.
PMID: 22649618
Acta Naturae. 2009 Oct;1(3):84-8.

The discovery of the pharmaceutical potential of small molecule inhibitors of oncogenic protein tyrosine kinases is one of the directions in target therapy in oncology. Presently, investigations aiming at developing new therapeutically important inhibitors have to be based on...

Cite
Rakitina TV, Yudkina OV, Smirnova EV, et al. Protein tyrosine kinase panel as a tool for anticancer drug design. Acta Naturae. 2009;1(3):84-8
Rakitina, T. V., Yudkina, O. V., Smirnova, E. V., & Lipkin, A. V. (2009). Protein tyrosine kinase panel as a tool for anticancer drug design. Acta naturae, 1(3), 84-8.
Rakitina, T V, et al. "Protein tyrosine kinase panel as a tool for anticancer drug design." Acta naturae vol. 1,3 (2009): 84-8.
Rakitina TV, Yudkina OV, Smirnova EV, Lipkin AV. Protein tyrosine kinase panel as a tool for anticancer drug design. Acta Naturae. 2009 Oct;1(3):84-8. PMID: 22649618; PMCID: PMC3347529.
Copy Download .nbib Format: NLM
Targeting lymphatic vessel functions through tyrosine kinases.

Journal of angiogenesis research

Williams SP, Karnezis T, Achen MG, Stacker SA.
PMID: 20698997
J Angiogenes Res. 2010 Aug 11;2:13. doi: 10.1186/2040-2384-2-13.

The lymphatic vascular system is actively involved in tissue fluid homeostasis, immune surveillance and fatty acid transport. Pathological conditions can arise from injury to the lymphatics, or they can be recruited in the context of cancer to facilitate metastasis....

Cite
Williams SP, Karnezis T, Achen MG, et al. Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res. 2010;2:13doi: 10.1186/2040-2384-2-13.
Williams, S. P., Karnezis, T., Achen, M. G., & Stacker, S. A. (2010). Targeting lymphatic vessel functions through tyrosine kinases. Journal of angiogenesis research, 213. https://doi.org/10.1186/2040-2384-2-13
Williams, Steven P, et al. "Targeting lymphatic vessel functions through tyrosine kinases." Journal of angiogenesis research vol. 2 (2010): 13. doi: https://doi.org/10.1186/2040-2384-2-13
Williams SP, Karnezis T, Achen MG, Stacker SA. Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res. 2010 Aug 11;2:13. doi: 10.1186/2040-2384-2-13. PMID: 20698997; PMCID: PMC2925338.
Copy Download .nbib Format: NLM
Ferulate, an Active Component of Wheat Germ, Ameliorates Oxidative Stress-Induced PTK/PTP Imbalance and PP2A Inactivation.

Toxicological research

Koh EM, Lee EK, Song CH, Song J, Chung HY, Chae CH, Jung KJ.
PMID: 30370008
Toxicol Res. 2018 Oct;34(4):333-341. doi: 10.5487/TR.2018.34.4.333. Epub 2018 Oct 15.

Ferulate is a phenolic compound abundant in wheat germ and bran and has been investigated for its beneficial activities. The aim of the present study is to evaluate the efficacy of ferulate against the oxidative stress-induced imbalance of protein...

Cite
Koh EM, Lee EK, Song CH, et al. Ferulate, an Active Component of Wheat Germ, Ameliorates Oxidative Stress-Induced PTK/PTP Imbalance and PP2A Inactivation. Toxicol Res. 2018;34(4):333-341doi: 10.5487/TR.2018.34.4.333.
Koh, E. M., Lee, E. K., Song, C. H., Song, J., Chung, H. Y., Chae, C. H., & Jung, K. J. (2018). Ferulate, an Active Component of Wheat Germ, Ameliorates Oxidative Stress-Induced PTK/PTP Imbalance and PP2A Inactivation. Toxicological research, 34(4), 333-341. https://doi.org/10.5487/TR.2018.34.4.333
Koh, Eun Mi, et al. "Ferulate, an Active Component of Wheat Germ, Ameliorates Oxidative Stress-Induced PTK/PTP Imbalance and PP2A Inactivation." Toxicological research vol. 34,4 (2018): 333-341. doi: https://doi.org/10.5487/TR.2018.34.4.333
Koh EM, Lee EK, Song CH, Song J, Chung HY, Chae CH, Jung KJ. Ferulate, an Active Component of Wheat Germ, Ameliorates Oxidative Stress-Induced PTK/PTP Imbalance and PP2A Inactivation. Toxicol Res. 2018 Oct;34(4):333-341. doi: 10.5487/TR.2018.34.4.333. Epub 2018 Oct 15. PMID: 30370008; PMCID: PMC6195880.
Copy Download .nbib Format: NLM
Trehalose Activates CRE-Dependent Transcriptional Signaling in HT22 Mouse Hippocampal Neuronal Cells: A Central Role for PKA Without cAMP Elevation.

Frontiers in molecular neuroscience

Maronde E.
PMID: 30405349
Front Mol Neurosci. 2018 Oct 22;11:386. doi: 10.3389/fnmol.2018.00386. eCollection 2018.

Cyclic adenosine 3',5'monophosphate (cAMP) regulated element binding protein (CREB) is a transcription factor involved in many different signaling processes including memory storage and retrieval. The mouse hippocampal neuronal cell line HT22 is widely used as a model system for...

Cite
Maronde E. Trehalose Activates CRE-Dependent Transcriptional Signaling in HT22 Mouse Hippocampal Neuronal Cells: A Central Role for PKA Without cAMP Elevation. Front Mol Neurosci. 2018;11:386doi: 10.3389/fnmol.2018.00386.
Maronde, E. (2018). Trehalose Activates CRE-Dependent Transcriptional Signaling in HT22 Mouse Hippocampal Neuronal Cells: A Central Role for PKA Without cAMP Elevation. Frontiers in molecular neuroscience, 11386. https://doi.org/10.3389/fnmol.2018.00386
Maronde, Erik. "Trehalose Activates CRE-Dependent Transcriptional Signaling in HT22 Mouse Hippocampal Neuronal Cells: A Central Role for PKA Without cAMP Elevation." Frontiers in molecular neuroscience vol. 11 (2018): 386. doi: https://doi.org/10.3389/fnmol.2018.00386
Maronde E. Trehalose Activates CRE-Dependent Transcriptional Signaling in HT22 Mouse Hippocampal Neuronal Cells: A Central Role for PKA Without cAMP Elevation. Front Mol Neurosci. 2018 Oct 22;11:386. doi: 10.3389/fnmol.2018.00386. eCollection 2018. PMID: 30405349; PMCID: PMC6204353.
Copy Download .nbib Format: NLM
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.

Pharmacological research

Roskoski R.
PMID: 34921994
Pharmacol Res. 2022 Jan;175:106037. doi: 10.1016/j.phrs.2021.106037. Epub 2021 Dec 15.

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 68 FDA-approved therapeutic agents that target about two...

Cite
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res. 2021;175:106037doi: 10.1016/j.phrs.2021.106037.
Roskoski, R. (2022). Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological research, 175106037. https://doi.org/10.1016/j.phrs.2021.106037
Roskoski, Robert. "Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update." Pharmacological research vol. 175 (2022): 106037. doi: https://doi.org/10.1016/j.phrs.2021.106037
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res. 2022 Jan;175:106037. doi: 10.1016/j.phrs.2021.106037. Epub 2021 Dec 15. PMID: 34921994; PMCID: PMC8691985.
Copy Download .nbib Format: NLM
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.

Pharmacological research

Roskoski R.
PMID: 33774181
Pharmacol Res. 2021 Jun;168:105579. doi: 10.1016/j.phrs.2021.105579. Epub 2021 Mar 26.

The discovery of the phosphatidylinositol 3-kinase (PI 3-kinase) pathway was a major advance in understanding eukaryotic signal transduction. The high frequency of PI 3-kinase pathway mutations in many cancers stimulated the development of drugs targeting these oncogenic mutants. The...

Cite
Roskoski R. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacol Res. 2021;168:105579doi: 10.1016/j.phrs.2021.105579.
Roskoski, R. (2021). Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological research, 168105579. https://doi.org/10.1016/j.phrs.2021.105579
Roskoski, Robert. "Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies." Pharmacological research vol. 168 (2021): 105579. doi: https://doi.org/10.1016/j.phrs.2021.105579
Roskoski R. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacol Res. 2021 Jun;168:105579. doi: 10.1016/j.phrs.2021.105579. Epub 2021 Mar 26. PMID: 33774181.
Copy Download .nbib Format: NLM
Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.

Biological & pharmaceutical bulletin

Muromoto R, Shimoda K, Oritani K, Matsuda T.
PMID: 34719635
Biol Pharm Bull. 2021;44(11):1585-1592. doi: 10.1248/bpb.b21-00609.

Tyrosine kinase 2 (Tyk2) is a member of the Janus family of protein tyrosine kinases (Jaks). Tyk2 associates with interferon (IFN)-α, IFN-β, interleukin (IL)-6, IL-10, IL-12, and IL-23 receptors and mediates their downstream signaling pathways. Based on our data...

Cite
Muromoto R, Shimoda K, Oritani K, et al. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. Biol Pharm Bull. 2021;44(11):1585-1592doi: 10.1248/bpb.b21-00609.
Muromoto, R., Shimoda, K., Oritani, K., & Matsuda, T. (2021). Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. Biological & pharmaceutical bulletin, 44(11), 1585-1592. https://doi.org/10.1248/bpb.b21-00609
Muromoto, Ryuta, et al. "Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases." Biological & pharmaceutical bulletin vol. 44,11 (2021): 1585-1592. doi: https://doi.org/10.1248/bpb.b21-00609
Muromoto R, Shimoda K, Oritani K, Matsuda T. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. Biol Pharm Bull. 2021;44(11):1585-1592. doi: 10.1248/bpb.b21-00609. PMID: 34719635.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 135 entries